 |
市場調査レポート
商品コード
1290674
消化性潰瘍治療薬市場：製品タイプ別、適応疾患別、流通チャネル別、地域別-規模、シェア、展望、機会分析、2023～2030年Peptic Ulcer Drugs Market, by Product Type by Disease Indication, Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 消化性潰瘍治療薬市場：製品タイプ別、適応疾患別、流通チャネル別、地域別-規模、シェア、展望、機会分析、2023～2030年 |
|
出版日: 2023年05月17日
発行: Coherent Market Insights
ページ情報: 英文 204 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
消化性潰瘍は、胃の内側と小腸の上部に発生する開放性の潰瘍です。消化性潰瘍の最も一般的な症状は、胃痛です。消化性潰瘍には以下のものがあります：胃の内側にできる胃潰瘍と、小腸の上部（十二指腸）の内側にできる十二指腸潰瘍があります。消化性潰瘍の最も一般的な原因は、ヘリコバクター・ピロリ（ピロリ菌）の感染と、イブプロフェン（アドビル、モトリンIBなど）やナプロキセンナトリウム（アレブ）などの非ステロイド性抗炎症薬（NSAIDs）の長期使用です。ストレスや辛い食べ物が消化性潰瘍の原因になることはありません。しかし、症状を悪化させる可能性はあります。
最も一般的な消化性潰瘍の症状は、灼熱の胃痛です。胃酸は痛みを悪化させ、空腹時も同様です。消化性潰瘍は、胃や小腸の最初の部分に開いた潰瘍ができる病気です。消化性潰瘍の多くは、細菌感染によって消化器系の保護膜が侵されることで発症します。鎮痛剤を頻繁に服用する人は潰瘍になりやすいと言われています。
市場力学
規制機関からの製品承認の増加が、予測期間中の市場の成長を促進すると予想されます。例えば、2021年12月、製薬会社Edenbridge Pharmaceuticals社は、米国食品医薬品局がグリコピロレート口腔内崩壊錠を消化性潰瘍の症状の軽減および消化性潰瘍の治療の補助剤として承認したと発表しました。
本調査の主な特徴
- 本レポートでは、世界の消化性潰瘍治療薬市場を詳細に分析し、2022年を基準年とした予測期間（2023年～2030年）の市場規模および年間平均成長率（CAGR%）を提供しています。
- さまざまなセグメントにおける潜在的な収益機会を解明し、この市場に対する魅力的な投資提案マトリクスを説明しています。
- また、市場促進要因、抑制要因、機会、新製品の発売または承認、市場動向、地域展望、主要企業が採用する競争戦略に関する重要な考察を提供します。
- 以下のパラメータ-企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略-に基づいて、世界の消化性潰瘍治療薬市場の主要企業をプロファイルしています。
- この調査の一部としてカバーされている主要企業は、Daewoong Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, GlaxoSmithKline plc.です。
- 本レポートから得られる知見は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にするでしょう。
- 消化性潰瘍治療薬の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
- 利害関係者は、世界の消化性潰瘍治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。
目次
第1章 調査目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場展望
- レポート概要
- 市場の定義と範囲
- エグゼクティブサマリー
- コヒーレント・オポチュニティ・マップ（COM）
第3章 市場力学、規制、動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 影響分析
- 最近の製品発表
- 疫学
- 合併、買収、共同研究
- 法規制のシナリオ
- 主な発展
- PEST分析
- パイプライン分析
第4章 消化性潰瘍治療薬の世界市場-コロナウイルス（COVID-19）のパンデミックの影響
- 経済的影響
- COVID-19の疫学的特徴
- 需給への影響
第5章 消化性潰瘍治療薬の世界市場：製品タイプ別、2017年～2030年
- プロトンポンプ阻害薬
- カリウム競合酸ブロッカー（P-CAB）
- 制酸剤
- H2-拮抗薬
- 抗生物質
- 潰瘍保護剤
第6章 消化性潰瘍治療薬の世界市場：疾患適応別、2017年～2030年
- 胃炎
- 胃潰瘍
- 十二指腸潰瘍
- 胃食道逆流症（GERD）
第7章 消化性潰瘍治療薬の世界市場：流通チャネル別、2017年～2030年
- 病院内薬局
- 小売薬局
- オンライン薬局
第8章 消化性潰瘍治療薬の世界市場：地域別、2017年～2030年
- 北米
- 米国
- カナダ
- ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他ラテンアメリカ
- 欧州
- 英国
- ドイツ
- イタリア
- フランス
- スペイン
- ロシア
- その他欧州
- アジア太平洋地域
- 中国
- インド
- 日本
- ASEAN
- オーストラリア
- 韓国
- その他アジア太平洋地域
- 中東地域
- GCC
- イスラエル
- その他中東地域
- アフリカ
- 北アフリカ
- 中央アフリカ
- 南アフリカ共和国
第9章 競合情勢
- Daewoong Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Pfizer Inc.
- AstraZeneca plc.
- RedHill Biopharma
- Cadila Healthcare Ltd.
- Novitium Pharma LLC.
- Boehringer Ingelheim GmbH
- Eisai Co. Ltd.
- Yuhan Corporation
- GlaxoSmithKline plc.
第10章 セクション
- 調査手法について
- 出版社について
目次
Product Code: CMI3246
Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain. Peptic ulcers include: Gastric ulcers that occur on the inside of the stomach and Duodenal ulcers that occur on the inside of the upper portion of your small intestine (duodenum). The most common causes of peptic ulcers are infection with the bacterium Helicobacter pylori (H. pylori) and long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin IB, others) and naproxen sodium (Aleve). Stress and spicy foods do not cause peptic ulcers. However, they can make your symptoms worse.
The most common peptic ulcer symptom is burning stomach pain. Stomach acid makes the pain worse, as does having an empty stomach. Peptic ulcer disease occurs when open sores, or ulcers, form in the stomach or first part of the small intestine. Many cases of peptic ulcer disease develop because a bacterial infection eats away the protective lining of the digestive system. People who frequently take pain relievers are more likely to develop ulcers.
Market Dynamics
An increase in product approval from the regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, in December 2021, Edenbridge Pharmaceuticals, a pharmaceutical company, announced that the U.S. Food and Drug Administration have approved glycopyrrolate orally disintegrating tablets to reduce the symptoms of a peptic ulcer and as an adjunct to treatment of peptic ulcers.
Key features of the study:
- This report provides an in-depth analysis of the global peptic ulcer drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global peptic ulcer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Daewoong Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, GlaxoSmithKline plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global peptic ulcer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peptic ulcer drugs market
Detailed Segmentation:
- Global Peptic Ulcer Drugs Market, By Product Type:
- Proton Pump Inhibitors
- Potassium-Competitive Acid Blocker (P-CAB)
- Antacids
- H2- Antagonist
- Antibiotics
- Ulcer Protective
- Global Peptic Ulcer Drugs Market, By Disease Indication:
- Gastitis
- Gastric Ulcer
- Duodenal Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Global Peptic Ulcer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Peptic Ulcer Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Daewoong Pharmaceutical Co., Ltd *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Co., Ltd.
- Pfizer Inc.
- AstraZeneca plc.
- RedHill Biopharma
- Cadila Healthcare Ltd.
- Novitium Pharma LLC.
- Boehringer Ingelheim GmbH
- Eisai Co. Ltd.
- Yuhan Corporation
- GlaxoSmithKline plc.
- Daewoong Pharmaceutical Co., Ltd *
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pipeline Analysis
4. Global Peptic Ulcer Drugs Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Peptic Ulcer Drugs Market, By Product Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Proton Pump Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Potassium-Competitive Acid Blocker (P-CAB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Antacids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- H2- Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Ulcer Protective
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Peptic Ulcer Drugs Market, By Disease Indication, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Gastitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Gastric Ulcer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Duodenal Ulcer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Gastroesophageal Reflux Disease (GERD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Peptic Ulcer Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global Peptic Ulcer Drugs Market, By Region, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Daewoong Pharmaceutical Co., Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RedHill Biopharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cadila Healthcare Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novitium Pharma LLC.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eisai Co. Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Yuhan Corporation
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
10. Section
- Research Methodology
- About Us
